M
-
F
,
8
am -
6
pm ET

How Alnylam Assist™ Can Help Your Patients

Alnylam Assist™ is committed to helping patients access therapy. Your patient will work with an Alnylam Case Manager to help them have a smooth treatment experience with AMVUTTRA® (vutrisiran) and answer questions they may have along the way.

Enroll Now

Alnylam Assist™ Support Overview

Your patient's Start Form has been submitted. Upon receipt of the Start Form, an Alnylam Case Manager will reach out to you and your patient within 2 business days. Your patient's Case Manager can help them with the following:

Alnylam Assist® - Understanding Your Benefits
Benefit Verification

Help determine patient-specific coverage requirements, which include the following:

Initiate a benefit verification for your patient and provide you and your patient with a benefit verification summary

Provide information about patient financial assistance programs for eligible patients,a if necessary

Alnylam Assist® - Treatment Coverage
Education on the prior authorizations, claims, and appeals processes

Explain the requirements and processes for prior authorizations, claims, and appeals, which include the following:

Research the payer requirements as part of the benefit verification process

Discuss the standard process for submitting a prior authorization and reimbursement claims

Investigate reasons for denied or rejected prior authorizations, claims, and/or appeals

Alnylam Assist® - Financial Assistance Options
Financial Assistance

Alnylam offers financial assistance programs for eligible patients. After being prescribed an Alnylam product, your patient can talk to an Alnylam Case Manager to learn more. Below are examples of two Alnylam financial assistance programs.a

Patient Assistance Program (PAP): Provides Alnylam product at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria

Commercial Copay Program: Covers certain out-of-pocket costs for eligible patients with commercial insuranceb

a  Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

b  Patients with Medicare, Medicaid, or other government sponsored insurance are not eligible for the Alnylam Assist™ Commercial Copay Program. Out-of-pocket costs for the administration of AMVUTTRA will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

Alnylam Assist® - Disease and Treatment Education
Disease and Treatment Education

Provide information to your patients:

A Patient Starter Kit, including educational materials designed to help patients understand AMVUTTRA and Alnylam Assist™

Education for your patients from a designated Alnylam Patient Education Liaison (PEL)* to help them gain a better understanding of hATTR amyloidosis and treatment.

*  PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice.

Alnylam Assist® - Facilitation of Product Orders
Ordering product for your patient

a  Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

b  Patients with Medicare, Medicaid, or other government sponsored insurance are not eligible for the Alnylam Assist™ commercial copay program. Out-of-pocket costs for the administration of AMVUTTRA will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

Alnylam Field Reimbursement Directors

Alnylam Field Reimbursement Directors (FRDs) are available to provide education about coverage, coding and reimbursement process for AMVUTTRA. FRDs will share their knowledge of:

AMVUTTRA billing and coding requirements

Chart documentation requirements

Payer requirements

Download Brochures and Guides

Healthcare Professionals

Alnylam Assist™ Support

Services Overview Brochure (PDF)

Alnylam Assist® Services Overview Brochure for HCPs Thumbnail - for AMVUTTRA™ (vutrisiran)

Download

Patients + Caregivers

Alnylam Assist™ Brochure (PDF)

 

Alnylam Assist® Brochure for Patients Thumbnail - for vutrisiran™ (vutrisiran)

Download

Where can I find the necessary forms and documents to enroll patients in Alnylam Assist™?

Alnylam Assist™ provides all the required forms and documents to enroll your patients, as well as downloadable educational resources. View the associated AMVUTTRA forms and documents ›

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

Enrolling Your Patients

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›

or

Alnylam Assist® Start Form - To Print And Fax

Print
& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle

IMPORTANT SAFETY INFORMATION

Reduced Serum Vitamin A Levels and Recommended Supplementation
AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions
The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

INDICATION

AMVUTTRA® (vutrisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.